Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377672 · ClinicalTrials.gov registry record · Phase 1
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
A Phase 1 study of SARS CoV 2 Infection, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04377672 is a Phase 1 study of SARS CoV 2 Infection that has completed, run by Johns Hopkins University. The registered enrollment target is 14 participants, below the 4,965-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04377672, a Phase 1 study of SARS CoV 2 Infection, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent exposure. This study will also measure the level of anti-SARS-CoV-2 antibodies in patient's blood after the administration of the convalescent plasma.
Conditions Studied
Interventions
- BIOLOGICAL Anti-SARS-CoV-2 Human Convalescent Plasma
Study Locations (1)
Maryland
- Johns Hopkins Hospitals - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04377672
The ClinicalTrials.gov registry entry for NCT04377672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,965-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (100% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 1 intervention - of which Anti-SARS-CoV-2 Human Convalescent Plasma is the first listed.
NCT04377672 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04377672 about?
NCT04377672 is a clinical study titled "Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)". The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent ...
What is the current status of trial NCT04377672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-05-28. Estimated completion is 2021-12-13.
What conditions does trial NCT04377672 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection.
What interventions are being tested in trial NCT04377672?
The interventions under investigation include: Anti-SARS-CoV-2 Human Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04377672?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04377672 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
Pancoronavirus Vaccine Study in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.